SGLT2 Inhibition Updates 2021 - SGLT2 Inhibition in Cardiorenal Disease

Published: 20 July 2021

  • Views:

    Views Icon 25026
  • Likes:

    Heart Icon 7
  • episode_image
    14m 38s
    Part 1 | Session 6 Panel Discussion Stefan Anker, Shelley Zieroth, Andrew JS Coats, Bernard Zinman, John JV McMurray, Katherine Tuttle
  • episode_image
    6m 58s
    Part 2 | Session 4 Panel Discussion Andrew JS Coats, Gerasimos Filippatos, Shelley Zieroth, Stefan Anker
  • episode_image
    50m 42s
    Part 3 | Session 2 Discussion Alice Cheng, Andrew JS Coats
Average (ratings)
No ratings
Your rating

Overview

Organised with scientific co-chairs Stefan Anker and Andrew Coats, this event includes presentations and panel discussions with a host of international thought-leaders. 

 

The SGLT2 Updates 2021 conference SGLT2 Inhibition in Cardiorenal Disease: Translating Evidence into Clinical Practice covers the place of SGLT2 inhibitors in the newly released guidelines of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) as well as their implementation in clinical practice.

 

In addition to plenary sessions and satellite symposia the conference featured a number of Meet The Expert breakout sessions discussing the implications in treatment of specific patient subgroups including patients with comorbidities.  Audience questions were submitted throughout and were addressed by the panel experts.

Educational Objectives

SGLT2 Inhibition in Cardiorenal Disease

  • Prepare cardiologists, nephrologists and endocrinologists to effectively manage patients with heart failure, individually and collaboratively
  • Apply findings from clinical trials into clinical practice
  • Describe the role of SGLT2 inhibitors in different patient subgroups, including patients with comorbidities
  • Evaluate the safety and cardiorenal benefits of glucose-lowering agents
  • Implement the new guidelines of the HFA of the ESC in clinical practice

Target Audience

  • Cardiologists
  • Nephrologists
  • Endocrinologists

More from this programme

Part 2

SGLT2 Inhibitors in Heart Failure: A Practical Approach

Part 3

Meet The Expert: Implications for Clinical Practice - Breakout 1

Totality of Evidence for the Cardiorenal Patient - discussion with Alice Cheung and Andrew Coats. Session supported by an unrestricted grant from AstraZeneca

Part 4

Meet The Expert: Implications for Clinical Practice - Breakout 2

SGLT2i and QoL Improvement - discussion with Shelley Zieroth and John Spertus.

Part 5

Meet The Expert: Implications for Clinical Practice - Breakout 3

Age groups and vulnerable patients with Gerasimos Filippatos and Giuseppe Rosano.

Part 7

SGLT2 Inhibitors for Heart Failure: The New Standard of Care

Industry Satellite Symposium supported by the Boehringer Ingelheim and Lilly alliance

Part 8

Meet The Expert: Implications for Clinical Practice - Breakout 4

Early Treatment Initiation in the Hospital Setting - discussion with Marc Petrie and Deepak Bhatt. Session supported by an unrestricted grant from AstraZeneca

Part 9

Meet The Expert: Implications for Clinical Practice - Breakout 5

Managing Patients with Comorbidities (T2D & CKD) - discussion with Paola Fioretto and Katherine Tuttle. Session supported by an unrestricted grant from AstraZeneca

Part 10

Meet The Expert: Implications for Clinical Practice - Breakout 6

Interdisciplinary Collaboration and Care Transitions - discussion with Subodh Verma. Session supported by an unrestricted grant from AstraZeneca

Faculty Biographies

Shelley Zieroth

Shelley Zieroth

Director, Heart Failure and Heart Transplant Clinics

Dr Shelley Zieroth is Professor at the College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, as well as Director of the Heart Failure and Heart Transplant Clinics at St Boniface Hospital in Winnipeg, Canada. She is also Head of the Medical Heart Failure Program for Cardiac Sciences Manitoba.

She is involved in several heart failure clinical trials as a PI, National Lead or Executive Committee member. She is the Past President of the Canadian Heart Failure Society and Co-Chair of the Canadian Cardiovascular Society Heart Failure Guidelines. She is co-chair of Canada’s largest annual heart failure meeting, HF Update, and Past President of the Federation of Medical Women of Canada.

Dr Shelley Zieroth is an Editorial Board member of Cardiac Failure Review.

View full profile
John Spertus

John Spertus

Cardiologist

Dr John A Spertus is a Cardiologist and Professor of Medicine at UMKC School of Medicine, Missouri, US.

Dr Spertus is a graduate of UCSF Medical School and completed his internal medicine, cardiology and health services training at the University of Washington.

His research focuses on methods for assessing patients’ health outcomes, measuring healthcare quality, and the use of information technology to guide medical decision-making based on risk-prediction models so that treatment can be safer, more cost-effective, evidence-based and patient-centered.

 

View full profile